Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.
Identifieur interne : 000638 ( PubMed/Corpus ); précédent : 000637; suivant : 000639Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.
Auteurs : Mohammad Khalid ; Basha Khan ; Fahad Al Rabiah ; Ruwaida Alismaili ; Sarfraz Saleemi ; Agha Muhammad Rehan-Khaliq ; Ihab Weheba ; Hail Al Abdely ; Magid Halim ; Quaid Johar Nadri ; Abdullah Mohsin Al Dalaan ; Mohamed Zeitouni ; Taimur Butt ; Eid Al MutairySource :
- Annals of Saudi medicine [ 0975-4466 ]
English descriptors
- KwdEn :
- Adolescent, Aged, Aged, 80 and over, Antiviral Agents (therapeutic use), Asymptomatic Infections, Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Delayed Diagnosis, Drug Therapy, Combination, Female, Humans, Interferon alpha-2, Interferon-alpha (therapeutic use), Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus, Pneumonia (virology), Polyethylene Glycols (therapeutic use), Recombinant Proteins (therapeutic use), Respiratory Insufficiency (virology), Ribavirin (therapeutic use), Saudi Arabia (epidemiology), Tertiary Care Centers, Time-to-Treatment.
- MESH :
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- diagnosis : Coronavirus Infections.
- drug therapy : Coronavirus Infections.
- epidemiology : Saudi Arabia.
- virology : Pneumonia, Respiratory Insufficiency.
- Adolescent, Aged, Aged, 80 and over, Asymptomatic Infections, Delayed Diagnosis, Drug Therapy, Combination, Female, Humans, Interferon alpha-2, Male, Middle Aged, Middle East Respiratory Syndrome Coronavirus, Tertiary Care Centers, Time-to-Treatment.
Abstract
Middle Eastern respiratory syndrome caused by novel coronavirus (MERS CoV) has been a major public health challenge since it was first described in 2012 in Saudi Arabia. So far, there is no effective treatment for this serious illness, which features a high mortality rate. We report an initial experience of the use of ribavirin and interferon (IFN)-a2b in the management of MERS CoV at a tertiary care hospital.
DOI: 10.5144/0256-4947.2014.396
PubMed: 25827696
Links to Exploration step
pubmed:25827696Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.</title>
<author><name sortKey="Khalid, Mohammad" sort="Khalid, Mohammad" uniqKey="Khalid M" first="Mohammad" last="Khalid">Mohammad Khalid</name>
<affiliation><nlm:affiliation>Dr. Mohammad Khalid, Department of Medicine, King Faisal Specialist Hospital & Research Center PO Box 3354 Riyadh 11211 Saudi Arabia, mkhalid@kfshrc.edu.sa.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Khan, Basha" sort="Khan, Basha" uniqKey="Khan B" first="Basha" last="Khan">Basha Khan</name>
</author>
<author><name sortKey="Al Rabiah, Fahad" sort="Al Rabiah, Fahad" uniqKey="Al Rabiah F" first="Fahad" last="Al Rabiah">Fahad Al Rabiah</name>
</author>
<author><name sortKey="Alismaili, Ruwaida" sort="Alismaili, Ruwaida" uniqKey="Alismaili R" first="Ruwaida" last="Alismaili">Ruwaida Alismaili</name>
</author>
<author><name sortKey="Saleemi, Sarfraz" sort="Saleemi, Sarfraz" uniqKey="Saleemi S" first="Sarfraz" last="Saleemi">Sarfraz Saleemi</name>
</author>
<author><name sortKey="Rehan Khaliq, Agha Muhammad" sort="Rehan Khaliq, Agha Muhammad" uniqKey="Rehan Khaliq A" first="Agha Muhammad" last="Rehan-Khaliq">Agha Muhammad Rehan-Khaliq</name>
</author>
<author><name sortKey="Weheba, Ihab" sort="Weheba, Ihab" uniqKey="Weheba I" first="Ihab" last="Weheba">Ihab Weheba</name>
</author>
<author><name sortKey="Al Abdely, Hail" sort="Al Abdely, Hail" uniqKey="Al Abdely H" first="Hail" last="Al Abdely">Hail Al Abdely</name>
</author>
<author><name sortKey="Halim, Magid" sort="Halim, Magid" uniqKey="Halim M" first="Magid" last="Halim">Magid Halim</name>
</author>
<author><name sortKey="Nadri, Quaid Johar" sort="Nadri, Quaid Johar" uniqKey="Nadri Q" first="Quaid Johar" last="Nadri">Quaid Johar Nadri</name>
</author>
<author><name sortKey="Al Dalaan, Abdullah Mohsin" sort="Al Dalaan, Abdullah Mohsin" uniqKey="Al Dalaan A" first="Abdullah Mohsin" last="Al Dalaan">Abdullah Mohsin Al Dalaan</name>
</author>
<author><name sortKey="Zeitouni, Mohamed" sort="Zeitouni, Mohamed" uniqKey="Zeitouni M" first="Mohamed" last="Zeitouni">Mohamed Zeitouni</name>
</author>
<author><name sortKey="Butt, Taimur" sort="Butt, Taimur" uniqKey="Butt T" first="Taimur" last="Butt">Taimur Butt</name>
</author>
<author><name sortKey="Al Mutairy, Eid" sort="Al Mutairy, Eid" uniqKey="Al Mutairy E" first="Eid" last="Al Mutairy">Eid Al Mutairy</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:25827696</idno>
<idno type="pmid">25827696</idno>
<idno type="doi">10.5144/0256-4947.2014.396</idno>
<idno type="wicri:Area/PubMed/Corpus">000638</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000638</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.</title>
<author><name sortKey="Khalid, Mohammad" sort="Khalid, Mohammad" uniqKey="Khalid M" first="Mohammad" last="Khalid">Mohammad Khalid</name>
<affiliation><nlm:affiliation>Dr. Mohammad Khalid, Department of Medicine, King Faisal Specialist Hospital & Research Center PO Box 3354 Riyadh 11211 Saudi Arabia, mkhalid@kfshrc.edu.sa.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Khan, Basha" sort="Khan, Basha" uniqKey="Khan B" first="Basha" last="Khan">Basha Khan</name>
</author>
<author><name sortKey="Al Rabiah, Fahad" sort="Al Rabiah, Fahad" uniqKey="Al Rabiah F" first="Fahad" last="Al Rabiah">Fahad Al Rabiah</name>
</author>
<author><name sortKey="Alismaili, Ruwaida" sort="Alismaili, Ruwaida" uniqKey="Alismaili R" first="Ruwaida" last="Alismaili">Ruwaida Alismaili</name>
</author>
<author><name sortKey="Saleemi, Sarfraz" sort="Saleemi, Sarfraz" uniqKey="Saleemi S" first="Sarfraz" last="Saleemi">Sarfraz Saleemi</name>
</author>
<author><name sortKey="Rehan Khaliq, Agha Muhammad" sort="Rehan Khaliq, Agha Muhammad" uniqKey="Rehan Khaliq A" first="Agha Muhammad" last="Rehan-Khaliq">Agha Muhammad Rehan-Khaliq</name>
</author>
<author><name sortKey="Weheba, Ihab" sort="Weheba, Ihab" uniqKey="Weheba I" first="Ihab" last="Weheba">Ihab Weheba</name>
</author>
<author><name sortKey="Al Abdely, Hail" sort="Al Abdely, Hail" uniqKey="Al Abdely H" first="Hail" last="Al Abdely">Hail Al Abdely</name>
</author>
<author><name sortKey="Halim, Magid" sort="Halim, Magid" uniqKey="Halim M" first="Magid" last="Halim">Magid Halim</name>
</author>
<author><name sortKey="Nadri, Quaid Johar" sort="Nadri, Quaid Johar" uniqKey="Nadri Q" first="Quaid Johar" last="Nadri">Quaid Johar Nadri</name>
</author>
<author><name sortKey="Al Dalaan, Abdullah Mohsin" sort="Al Dalaan, Abdullah Mohsin" uniqKey="Al Dalaan A" first="Abdullah Mohsin" last="Al Dalaan">Abdullah Mohsin Al Dalaan</name>
</author>
<author><name sortKey="Zeitouni, Mohamed" sort="Zeitouni, Mohamed" uniqKey="Zeitouni M" first="Mohamed" last="Zeitouni">Mohamed Zeitouni</name>
</author>
<author><name sortKey="Butt, Taimur" sort="Butt, Taimur" uniqKey="Butt T" first="Taimur" last="Butt">Taimur Butt</name>
</author>
<author><name sortKey="Al Mutairy, Eid" sort="Al Mutairy, Eid" uniqKey="Al Mutairy E" first="Eid" last="Al Mutairy">Eid Al Mutairy</name>
</author>
</analytic>
<series><title level="j">Annals of Saudi medicine</title>
<idno type="eISSN">0975-4466</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Asymptomatic Infections</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Delayed Diagnosis</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Pneumonia (virology)</term>
<term>Polyethylene Glycols (therapeutic use)</term>
<term>Recombinant Proteins (therapeutic use)</term>
<term>Respiratory Insufficiency (virology)</term>
<term>Ribavirin (therapeutic use)</term>
<term>Saudi Arabia (epidemiology)</term>
<term>Tertiary Care Centers</term>
<term>Time-to-Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Polyethylene Glycols</term>
<term>Recombinant Proteins</term>
<term>Ribavirin</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Saudi Arabia</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Pneumonia</term>
<term>Respiratory Insufficiency</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Asymptomatic Infections</term>
<term>Delayed Diagnosis</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Middle East Respiratory Syndrome Coronavirus</term>
<term>Tertiary Care Centers</term>
<term>Time-to-Treatment</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Middle Eastern respiratory syndrome caused by novel coronavirus (MERS CoV) has been a major public health challenge since it was first described in 2012 in Saudi Arabia. So far, there is no effective treatment for this serious illness, which features a high mortality rate. We report an initial experience of the use of ribavirin and interferon (IFN)-a2b in the management of MERS CoV at a tertiary care hospital.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25827696</PMID>
<DateCompleted><Year>2015</Year>
<Month>11</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">0975-4466</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>34</Volume>
<Issue>5</Issue>
<PubDate><MedlineDate>2014 Sep-Oct</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Annals of Saudi medicine</Title>
<ISOAbbreviation>Ann Saudi Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.</ArticleTitle>
<Pagination><MedlinePgn>396-400</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.5144/0256-4947.2014.396</ELocationID>
<Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Middle Eastern respiratory syndrome caused by novel coronavirus (MERS CoV) has been a major public health challenge since it was first described in 2012 in Saudi Arabia. So far, there is no effective treatment for this serious illness, which features a high mortality rate. We report an initial experience of the use of ribavirin and interferon (IFN)-a2b in the management of MERS CoV at a tertiary care hospital.</AbstractText>
<AbstractText Label="DESIGN AND SETTINGS" NlmCategory="METHODS">A case series of 6 patients admitted with a confirmed diagnosis of MERS CoV were treated with ribavirin and IFN-a2b in addition to supportive management. The patients' demographics, clinical parameters, and outcomes were recorded. Fifty-four close contacts of these patients were screened for MERS CoV.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Six patients with MERS CoV infection were included in this study. Four cases featured symptomatic disease, including pneumonia and respiratory failure, while 2 were asymptomatic close contacts of the MERS CoV patients. The MERS CoV infection was confirmed by reverse transcription-polymerase chain reaction detection of the consensus viral RNA targets upstream of the E gene (UPE) and open reading frame (ORF1b) on a sputum sample. The patients' demographics, comorbid conditions, time to diagnosis and initiation of treatment, and clinical outcomes were recorded.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Three out of 6 patients who had comorbid conditions died during the study period, while 3 had suc.cessful outcomes. The diagnosis and treatment was delayed by an average of 15 days in those patients who died. Only 2 close contacts out of the 54 screened (3.7%) were positive for MERS CoV.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with ribavirin and IFN-a2b may be effective in patients infected with MERS CoV. There appears to be a low infectivity rate among close contacts of MERS CoV patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalid</LastName>
<ForeName>Mohammad</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Dr. Mohammad Khalid, Department of Medicine, King Faisal Specialist Hospital & Research Center PO Box 3354 Riyadh 11211 Saudi Arabia, mkhalid@kfshrc.edu.sa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khan</LastName>
<ForeName>Basha</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Al Rabiah</LastName>
<ForeName>Fahad</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Alismaili</LastName>
<ForeName>Ruwaida</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Saleemi</LastName>
<ForeName>Sarfraz</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rehan-Khaliq</LastName>
<ForeName>Agha Muhammad</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weheba</LastName>
<ForeName>Ihab</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Al Abdely</LastName>
<ForeName>Hail</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Halim</LastName>
<ForeName>Magid</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nadri</LastName>
<ForeName>Quaid Johar</ForeName>
<Initials>QJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Al Dalaan</LastName>
<ForeName>Abdullah Mohsin</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zeitouni</LastName>
<ForeName>Mohamed</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Butt</LastName>
<ForeName>Taimur</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Al Mutairy</LastName>
<ForeName>Eid</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Saudi Arabia</Country>
<MedlineTA>Ann Saudi Med</MedlineTA>
<NlmUniqueID>8507355</NlmUniqueID>
<ISSNLinking>0256-4947</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber>
<NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>49717AWG6K</RegistryNumber>
<NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>G8RGG88B68</RegistryNumber>
<NameOfSubstance UI="C417083">peginterferon alfa-2b</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058345" MajorTopicYN="N">Asymptomatic Infections</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065207" MajorTopicYN="Y">Middle East Respiratory Syndrome Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N">Saudi Arabia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>11</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25827696</ArticleId>
<ArticleId IdType="doi">10.5144/0256-4947.2014.396</ArticleId>
<ArticleId IdType="pmc">PMC6074560</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):726-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23782860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Jun 26;370(26):2499-505</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24896817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014 Feb 25;5(2):e00884-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24570370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2014 Apr 29;5(3):e01146-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24781747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2013;3:1686</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Curr. 2013 Jul 17;5:null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23884087</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000638 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= CovidV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:25827696 |texte= Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25827696" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidV1
This area was generated with Dilib version V0.6.33. |